Drug Trial Radar · NCT03181399
Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)
Last checked: Nov 20, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Apr 18, 2018
Primary completion
Sep 10, 2023
Study completion Sep 10, 2023
Sponsor
- Lead sponsor
- University of Texas Southwestern Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Jun 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 24 months, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Forty-five subjects receiving no dietary therapy with a proven G1D diagnosis will be enrolled. To evaluate the effect of C7 supplementation of a regular diet on a EEG activity in addition to IQ, language, working memory, processing speed, emotional and behavioral functioning, ataxia, and other neuropsychological and neurological performance indices in children and adults genetically diagnosed with G1D receiving a regular diet at enrollment.
Conditions
- GLUT1DS1
- Epilepsy
- Glut1 Deficiency Syndrome 1, Autosomal Recessive
- Glucose Metabolism Disorders
- Glucose Transport Defect
- Glucose Transporter Type 1 Deficiency Syndrome
- Glucose Transporter Protein Type 1 Deficiency Syndrome
Interventions
TriheptanoinDrug
. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Neuropsychological Score of Sustained AttentionTime frame: Change post 6 months of treatment
- Neuropsychological Score of Sustained AttentionTime frame: Change after 3 months off treatment
- Neuropsychological Score of Working Memory Index Scale (WMI)Time frame: Change post 6 months of treatment
- Neuropsychological Score of Working Memory Index Scale (WMI)Time frame: Change after 3 months off-treatment
- Neuropsychological Score of Processing Speed Index (PSI)Time frame: Change post 6 months of treatment
- Neuropsychological Score of Processing Speed Index (PSI)Time frame: Change after 3 months off-treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas Southwestern Medical Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.